Concomitant combination of active immunotherapy and carboplatin- or paclitaxel-based chemotherapy improves anti-tumor response

Cancer Immunology, Immunotherapy

Volumn 62, Issue 3, 2013, Pages 455-469

  Diaz, Y ^a   Tundidor, Y ^a   Lopez, A ^a   Leon, K ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Active immunotherapy; Anti tumor response; Chemotherapy; Concomitant treatment

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; OVALBUMIN BASED FREUND ADJUVANT VACCINE; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; OVALBUMIN;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEASIBILITY STUDY; FEMALE; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECT; HUMAN; IMMUNOLOGY; LYMPHOCYTE; MULTIMODALITY CANCER THERAPY; NEOPLASM;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARBOPLATIN; COMBINED MODALITY THERAPY; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS; OVALBUMIN; PACLITAXEL;

MLCS; MLOWN;

EID: 84877117925     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1345-y     Document Type: Article

References (67)

1. Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5:263-274 (Pubitemid 40488632)
2. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905-4913 (Pubitemid 36554719)
3. Polak L, Turk JL (1974) Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 249:654-656
4. Zhang L, Dermawan K, Jin M, Liu R, Zheng H, Xu L, Zhang Y, Cai Y, Chu Y, Xiong S (2008) Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin Immunol 129:219-229
5. Kang TH, Lee JH, Song CK, Han HD, Shin BC, Pai SI, Hung CF, Trimble C, Lim JS, Kim TW et al (2007) Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 67:802-811 (Pubitemid 46192221)
6. Song CK, Han HD, Noh KH, Kang TH, Park YS, Kim JH, Park ES, Shin BC, Kim TW (2007) Chemotherapy enhances CD8(+) T cell-mediated antitumor immunity induced by vaccination with vaccinia virus. Mol Ther 15:1558-1563 (Pubitemid 47099313)
7. Han HD, Song CK, Park YS, Noh KH, Kim JH, Hwang T, Kim TW, Shin BC (2008) A chitosan hydrogel-based cancer drug delivery system exhibits synergistic antitumor effects by combining with a vaccinia viral vaccine. Int J Pharm 350:27-34 (Pubitemid 351146677)
8. Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G et al (2008) Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother 31:132-147
9. Hayakawa M, Kawaguchi S, Ishii S, Murakami M, Uede T (1997) B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells. Int J Cancer 71:1091-1102 (Pubitemid 27252895)
10. Zheng SJ, Zheng SP, Huang FY, Jiao CL, Wu RL (2007) Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model. World J Gastroenterol 13:2484-2489
11. Akbulut H, Tang Y, Akbulut KG, Maynard J, Zhang L, Deisseroth A (2006) Antitumor immune response induced by it injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer. Mol Cancer Ther 5:1975-1985 (Pubitemid 44336569)
12. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689-3697 (Pubitemid 32694981)
13. Ko HJ, Kim YJ, Kim YS, Chang WS, Ko SY, Chang SY, Sakaguchi S, Kang CY (2007) A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67:7477-7486 (Pubitemid 47206577)
14. Kim CH, Woo SJ, Park JS, Kim HS, Park MY, Park SD, Hong YK, Kim TG (2007) Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 122:615-622 (Pubitemid 350075960)
15. Park SD, Kim CH, Kim CK, Park JA, Sohn HJ, Hong YK, Kim TG (2007) Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine 25:3485-3491 (Pubitemid 46528001)
16. Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13-27 (Pubitemid 39458111)
17. Gabrilovich DI, Chen HL, Girgis KR (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096-1103 (Pubitemid 26338628)
18. Loeffler CM, Smyth MJ, Longo DL (1992) Immunoregulation in cancer-bearing hosts: downregulation of gene expression and cytotoxic function in CD8 T cells. J Immunol 149:949-956
19. Qin Z, Noffz G, Mohauot M (1997) Interleukin-10 prevent dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol 159:770-776 (Pubitemid 127484228)
20. Malmberg KJ (2004) Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53:879-892 (Pubitemid 39312655)
21. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY et al (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517-1526 (Pubitemid 34533020)
22. Arteaga CL (2003) ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284:122-130 (Pubitemid 36331971)
23. Garcia B, Neninger E, de la Torre A, Leonard I, Martinez R, Viada C, Gonzalez G, Mazorra Z, Lage A, Crombet T (2008) Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 14:840-846 (Pubitemid 351231168)
24. Gonzalez G, Crombet T, Catala M, Mirabal V, Hernandez J, Gonzalez Y, Marinello P, Guillen G, Lage A (1998) A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 9:431-435 (Pubitemid 28273037)
25. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, Neninger E, Garcia B, Mulet A, Perez R et al (2003) Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 14:461-466 (Pubitemid 36367426)
26. Montero E, Valdes M, Avellanet J, Lopez A, Perez R, Lage A (2009) Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. Vaccine 27:2230-2239
27. Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J (2008) Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers. Clin Cancer Res 14:6456-6468
28. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM (2009) Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 58:615-628
29. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546-2553 (Pubitemid 47041228)
30. Munn DH, Sharma MD, Hou D, Baban B, Lee JR, Antonia SJ, Messina JL, Chandler P, Koni PA, Mellor AL (2004) Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280-290 (Pubitemid 39071633)
31. Schnurr M, Chen Q, Shin A, Chen W, Toy T, Jenderek C, Green S, Miloradovic L, Drane D, Davis ID et al (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105:2465-2472 (Pubitemid 40387047)
32. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, Clay TM (2008) Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 112:610-618
33. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY et al (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517-1526 (Pubitemid 34533020)
34. Krishna IV, Vanaja GR, Kumar NS, Suman G (2009) Cytotoxic studies of anti-neoplastic drugs on human lymphocytes - in vitro studies. Cancer Biomarkers 5:261-272
35. Dunde S, Geissler A, Olfe J, Starke A, Domanska G, Schuett C, Kiank-Nussbaum C (2011) Side effects of control treatment can conceal experimental data when studying stress responses to injection and psychological stress in mice. Lab Anim (NY) 40:119-128
36. Rinehart J, Keville L, Measel J, Spiekerman AM, Burke K (1995) Corticosteroid alteration of carboplatin-induced hematopoietic toxicity in a murine model. Blood 86:4493-4499
37. Wang H, Li M, Rinehart JJ, Zhang R (2004) Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine. Cancer Chemother Pharmacol 53:459-467 (Pubitemid 38680242)
38. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336-344 (Pubitemid 39255944)
39. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862-2868 (Pubitemid 40446280)
40. Lee M, Yea SS, Jeon YJ (2000) Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int J Immunopharmacol 22:615-621 (Pubitemid 30320801)
41. Yuan L, Wu L, Chen J, Wu Q, Hu S (2010) Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Vaccine 28:4402-4410
42. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380-384 (Pubitemid 32467048)
43. Markasz L, Skribek H, Uhlin M, Otvos R, Flaberg E, Eksborg S, Olah E, Stuber G, Szekely L (2008) Effect of frequently used chemotherapeutic drugs on cytotoxic activity of human cytotoxic T-lymphocytes. J Immunother 31:283-293 (Pubitemid 351441005)
44. Samanta S, Alam SM, Basu S, Maji T, Roy DK, Jha T (2007) Chemoimmunotherapeutic approach to prolonged survival time in combination with immunization and glutamic acid derivatives with antitumor activity in tumor-bearing mice. Biol Pharm Bull 30:2334-2339 (Pubitemid 350223738)
45. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB (2004) Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 6:R275-R283
46. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont JA, Urba W, Blumenstein B, Sacks N, Keilholz U et al (2007) A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30:1-15 (Pubitemid 46052199)
47. Weng W, Czerwinski D, Levy R (2007) Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 109:951-953 (Pubitemid 46220638)
48. Cassidy PB, Moos PJ, Kelly RC, Fitzpatrick FA (2002) Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin Cancer Res 8:846-855 (Pubitemid 34742117)
49. Collins TS, Lee LF, Ting JP (2000) Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol Immunother 49:78-84 (Pubitemid 30431643)
50. Crown J, O'Leary M (2000) The taxanes: an update. Lancet 355:1176-1178 (Pubitemid 30172946)
51. Kirikae T, Ojima I, Fuero-Oderda C, Lin S, Kirikae F, Hashimoto M, Nakanoc M (2000) Structural significance of the acyl group at the C-10 position and the A ring of the taxane core of paclitaxel for inducing nitric oxide and tumor necrosis factor production by murine macrophages. FEBS Lett 478:221-226 (Pubitemid 30621621)
52. Kim YM, Paik SG (2005) Induction of expression of inducible nitric oxide synthase by taxol in murine macrophage cells. Biochem Biophys Res Commun 326:410-416 (Pubitemid 39593562)
53. El-Gazzar A, Perco P, Eckelhart E, Anees M, Sexl V, Mayer B, Liu Y, Mikulits W, Horvat R, Pangerl T et al (2010) Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer. Mol Cancer Ther 9:1007-1018
54. Geller MA, Bui-Nguyen TM, Rogers LM, Ramakrishnan S (2010) Chemotherapy induces macrophage chemoattractant protein-1 production in ovarian cancer. Int J Gynecol Cancer 20:918-925
55. Gonzalez G, Lage A (2007) Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr Cancer Drug Targets 7:229-241 (Pubitemid 46699074)
56. Campbell MJ, Esserman L, Levy R (1988) Immunotherapy of established murine B cell lymphoma. J Immunol 141:3227-3233
57. Rodriguez PC, Neninger E, García B, Popa X, Viada C, Luaces P, González G, Lage A, Montero E, Crombet T (2011) Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an epidermal growth factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients. J Immune Based Ther Vaccines 9:7
58. Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, Mazorra Z, Fleites G, González M, Wilkinson B et al (2009) Combining an EGF-based cancer vaccine with chemotherapy in advanced non-small cell lung cancer. J Immunother 32:92-99
59. Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, Takahashi K, Nakahara K, Honma S, Tanaka M, Mizoguchi J et al (2007) Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98:605-611 (Pubitemid 46562753)
60. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, Beetham P, Tsang KY, Grosenbach DW, Feldman J et al (2006) A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 12:1260-1269 (Pubitemid 43342517)
61. Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishihara Y, Yamada A et al (2007) Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 98:1113-1119 (Pubitemid 46865399)
62. Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, Moore M, von Mehren M, Dalfen R, Heim WJ et al (2008) Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 14:4843-4849
63. Weihrauch MR, Ansen S, Jurkiewicz E, Geisen C, Xia Z, Anderson KS, Gracien E, Schmidt M, Wittig B, Diehl V et al (2005) Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 11:5993-6001 (Pubitemid 41170331)
64. Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E et al (2008) Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14:1455-1463 (Pubitemid 351413929)
65. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Levi J, Daphtary MM, Biedrzycki B, Wolff AC et al (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27:5911-5918
66. von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT et al (2001) The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 7:1181-1191 (Pubitemid 32708668)
67. Small E, Demkow T, Gerritson W et al (2009) A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). GU ASCO